Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cellular Immunology

• Publication date

  2006-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CELLIMM.2006.11.002PMID 17207783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activated T cells express the OX40 ligand: requirements for induction and costimulatory function

  2006cited by this paper
• Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells1

  2005cited by this paper
• Cutting Edge: Bcl-3 Up-Regulation by Signal 3 Cytokine (IL-12) Prolongs Survival of Antigen-Activated CD8 T Cells1

  2005cited by this paper
• Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

  2005cited by this paper
• TNF/TNFR family members in costimulation of T cell responses.

  2005cited by this paper
• Comparative Analysis of Antigen Loading Strategies of Dendritic Cells for Tumor Immunotherapy

  2004cited by this paper
• Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses

  2004cited by this paper
• IL‐12 and IL‐23: master regulators of innate and adaptive immunity

  2004cited by this paper
• Dendritic cell-based cancer immunotherapy.

  2003cited by this paper
• The First 1000 Dendritic Cell Vaccinees

  2003cited by this paper
• Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells

  2003cited by this paper
• Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

  2003cited by this paper
• Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

  2003cited by this paper
• Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1

  2003cited by this paper
• Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.

  2003cited by this paper
• Interleukin-12 and the regulation of innate resistance and adaptive immunity

  2003cited by this paper
• Current developments in cancer vaccines and cellular immunotherapy.

  2003cited by this paper
• The biology of IL-12: coordinating innate and adaptive immune responses.

  2003cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion.

  2002cited by this paper
• Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses

  2002cited by this paper
• Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-121

  2002cited by this paper
• The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice1

  2002cited by this paper
• CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8+ T Cells1

  2002cited by this paper
• Tumour cell–dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen‐glycol versus electro‐fusion protocols

  2002cited by this paper
• Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

  2002cited by this paper
• the Antitumor Immune Response Strategies for Antigen Loading of Dendritic Cells to Enhance Updated

  2002cited by this paper
• OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.

  2002cited by this paper
• T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.

  2001cited by this paper
• Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity

  2001cited by this paper
• CD134L Expression on Dendritic Cells in the Mesenteric Lymph Nodes Drives Colitis in T Cell-Restored SCID Mice1

  2001cited by this paper
• Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.

  2001cited by this paper
• Active immunization against cancer with dendritic cells: The near future

  2001cited by this paper
• Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

  2001cited by this paper
• Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1

  2001cited by this paper
• Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand

  2000cited by this paper
• Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1

  2000cited by this paper
• Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

  2000cited by this paper
• Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.

  1999cited by this paper
• Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

  1999cited by this paper
• Cancer vaccines

  1998cited by this paper
• Dendritic cells require maturation via CD40 to generate protective antitumor immunity.

  1998cited by this paper
• Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

  1998cited by this paper
• Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.

  1998cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response

  1996cited by this paper
• Electrofusion of mammalian cells.

  1995cited by this paper
• Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand

  1995cited by this paper
• Electrofusion.

  1993cited by this paper
• Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy.

  1991cited by this paper
• Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

  1991cited by this paper
• Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium.

  1991cited by this paper

• Challenges and opportunities in the development of combination immunotherapy with OX40 agonists

  2023cites this paper
• Proliferative Activity and Subpopulation Pattern of Cells in Murine Thymus and Spleen on the Model of Graft-Versus-Host Chronic Reaction under Various Diurnal Regimens of IL-2 Administration

  2013cites this paper
• This information is current as Subsets in SIV-Infected Macaques or IL-15 Induces Distinct CD8 Memory Immunodeficiency Virus (SIV)-DNA+IL-12 Therapeutic Vaccination with Simian

  2013cites this paper
• Dendritic cell-based vaccines: barriers and opportunities.

  2012cites this paper
• Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy

  2012cites this paper
• Treatment of Melanoma with Agonist Immune Costimulatory Agents

  2012cites this paper
• Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

  2011cites this paper
• HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.

  2011cites this paper
• Dendritic cell-tumor cell fusion vaccines.

  2011cites this paper
• Cell fusion in health and disease

  2011cites this paper
• Cancer Vaccine by Fusions of Dendritic and Cancer Cells

  2010cites this paper
• Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells

  2010cites this paper
• Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

  2010cites this paper
• The effect of aging on OX40 agonist-mediated cancer immunotherapy

  2009cites this paper
• OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age

  2009cites this paper
• The role of OX40-mediated co-stimulation in T-cell activation and survival.

  2009cites this paper
• Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results

  2009cites this paper
• Age withEffector T Cell Differentiation Decreases OX 40-Enhanced Tumor Rejection and

  2009cites this paper
• Role of Lymph Nodes in Immunotherapy of Malignant Tumors

  2009cites this paper
• Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

  2009cites this paper
• Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

  2008cites this paper
• Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques1

  2008cites this paper
• Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids.

  2008cites this paper
• Chronic and Acute Alcohol Exposure Prevents Monocyte-Derived Dendritic Cells from Differentiating and Maturing

  2008cites this paper
• Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.

  2008cites this paper